Use of non-steroid anti-inflammatory preparations for prevention of acute pancreatitis after endoscopic retrograde cholangiopancreatography (literature review)
Abstract
Non-steroid anti-inflammatory preparations (NSAlDs) - a unique class of the medical products possessing analgesic, anti-inflammatory and febrifugal effect. NSAlDs are widely used in various branches of medicine, especially at a pathology of the oporno-impellent device for knocking over of a pain after traumas, and also for symptomatic therapy of acute and chronic rheumatic diseases. Endoscopic retrograde cholangiopancreatography (ERCP) is one of the most important methods for diagnosis of diseases of the pancreatobiliary zone. ln addition to visualizing intraductal changes, this technique allows a wide range of surgical procedures, such as papillosfinkterotomiya, removal of stones, stenting and more. Unfortunately, during ERCP, serious complications may arise, primarily acute pancreatitis. To prevent the development of this pathology are offered a variety of technical and pharmacological approaches, but not all of them have proven effective in clinical trials. One of the most successful means for the prevention of post-ERCP acute pancreatitis was the use of nonsteroidal anti-inflammatory drugs. Appointment NSAlDs at carrying out ERCP - in an hour to - or is direct after procedure, essentially improves its shipping. First of all it is a question of reduction of number and reduction of weight of ERCP - associated acute pancreatitis potentially menacing to life of complication. Though in clinical researches it has not been shown authentic decrease mortality from the given pathology, nevertheless, it is necessary to think that active preventive maintenance will allow to rescue patients from the destruction caused heavy iatrogenic by a pancreatitis. This review is devoted to an analysis of published data on the subject.
About the Authors
E. V. Moroz
Central Military Clinical Hospital named after Acad. N.N. Burdenko
Russian Federation
Russian Federation
A. A. Sokolov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
E. N. Artemkin
Central Military Clinical Hospital named after Acad. N.N. Burdenko
Russian Federation
Russian Federation
References
1. Манцеров М.П., Мороз Е.В. Реактивный панкреатит после эндоскопических манипуляций на большом дуоденальном сосочке // РЖГГК. - 2007. -№ 3. - С. 14-23
2. Матвийчук Б.О., Кушнирук А.И., Клецко И.Я., Тумак И.Я. Комплексная профилактика острого панкреатита после рентгенэндоскопических транспапиллярных вмешательств // Украинский журнал хирургии. - 2013. - № 3 (22). - С. 35-41
3. Мороз Е.В., Ардашев В.Н., Манцеров М.П. Диагностика, профилактика и лечение реактивного панкреатита, возникающего после эндоскопической ретроградной холангиопанкреатографии (ЭРХПГ) // Общая реаниматология. - 2006. - № 5. - С. 37-41
4. Яхно Н.Н., Кукушкина М.Л. Боль (практическое руководство для врачей). - 2012. - 512 c
5. Baron T., Irani S. (2014). Prevention of post-ERCP pancreatitis. Minerva Med., 105 (2), 129-136.
6. Brand M., Bizos D., O’Farrell P. Jr. (2010). Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev., 10, doi: 10.1002/14651858.CD007345.pub2.
7. Cheon Y.K., Cho K.B., Watkins J.L., McHenry L. et al. (2007). Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest. Endosc., 66 (6), 1126-1132.
8. Cobb T.K., Pierce J.R. Jr. (1992). Acute pancreatitis associated with ketoprofen. South Med. J., 85 (4), 430-431.
9. Concepciôn-Marti'n M., Gômez-Oliva C., Juanes A. (2014). Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial. Endoscopy, Jun 30.
10. Cotton P.B., Garrow D.A., Gallagher J., Romagnuolo J. (2009). Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest. Endosc., 70 (1), 80-88.
11. Ding X., Chen M., Huang S., Zhang S. et al. (2012) Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest. Endosc., 76 (6), 1152-1159.
12. Dumonceau J.M., Andriulli A., Elmunzer B.J., Mariani A. et al. (2014). Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
13. Döbrönte Z., Szepes Z., Izbéki F., Gervain J. et al. (2014). Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis? World J. Gastroenterol., 20 (29), 1015110157.
14. Elmunzer B.J., Higgins P.D., Saini S.D., Scheiman J.M. et al. United States cooperative for outcomes research in endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and costbenefit analyses using prospective clinical trial data. Am. J. Gastroenterol., 108 (3), 410-415.
15. Famularo G., Bizzarri C., Nicotra G.C. (2002). Acute pancreatitis caused by ketorolac tromethamine. J. Clin. Gastroenterol., 34 (3), 283-284.
16. Hanna M.S., Portal A.J., Dhanda A.D., Przemioslo R (2014). UK wide survey on the prevention of post-ERCP pancreatitis. Frontline Gastroenterol., 5 (2), 103-110.
17. Iorgulescu A., Sandu I., Turcu F., Iordache N. (2013). Post-ERCP acute pancreatitis and its risk factors. J. Med. Life., 6 (1), 109-113.
18. Kochar B., Akshintala V.S., Afghani E., Elmunzer B.J. et al. (2014). Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest. Endosc., Aug 1.
19. Khan I.H., Edward N. (1993). Pancreatitis associated with diclofenac. Postgrad. Med. J., 69 (812), 486-487.
20. Leerhoy B., Nordholm-Carstensen A., Novovic S., Hansen M.B. et al. (2014). Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: Results from a Danish cohort study. Pancreas, Jul 7.
21. Magill P., Ridgway P.F., Conlon K.C., Neary P. (2006). A case of probable ibuprofen-induced acute pancreatitis. JOP, 7 (3), 311-314.
22. Mennecier D., Ceppa F., Sinayoko.L, Corberand D. et al. Acute pancreatitis after treatment by celecoxib. Gastroenterol. Clin. Biol., 31 (8-9), 668-669.
23. Murray B., Carter R., Imrie C., Evans S. et al. (2003). Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology, 124 (7), 1786-1791.
24. Otsuka T., Kawazoe S., Nakashita S., Kamachi S. et al. (2012). Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J. Gastroenterol., 47 (8), 912-917.
25. Omata F., Deshpande G., Tokuda Y., Takahashi O. et al. (2010). Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J. Gastroenterol., 45 (8), 885895.
26. Puig I., Calvet X., Baylina M., Isava À. et al. (2014). How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and metaanalysis. PLoS One, 9 (3), e92922.
27. Sorensen H.T., Jacobsen J., Norgaard M., Pedersen L. et al. (2006). Newer cyclooxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment. Pharmacol. Ther., 24 (1), 111-116.
28. Sethi S., Sethi N., Wadhwa V., Garud S. et al. (2014). A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas, 43 (2), 190-197.
29. Senol A., Saritas U., Demirkan H. (2009). Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J. Gastroenterol., 15 (32), 3999-4004.
30. Tenner S., Baillie J., DeWitt J., Vege S.S. (2013). American College of Gastroenterology guideline: management of acute pancreatitis. Am. J. Gastroenterol., 108 (9), 1400-1415.
31. Tsujino T.L., Kawabe T., Omata M. (2007). Antiproteases in preventing post-ERCP acute pancreatitis. JOP, 8 (4), 509-517.
32. Wamsteker E.J. (2014). Endoscopic approach to the diagnosis and treatment of pancreatic disease. Curr. Opin. Gastroenterol., 30 (5), 524-530.
33. Yuhara H., Ogawa M., Kawaguchi Y., Igarashi M. et al. (2014). Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J. Gastroenterol., 49 (3), 388-399.
34. Zhang Y., Chen Q.B., Gao Z.Y., Xie W.F. (2009). Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses. Aliment. Pharmacol. Ther.,
35. (11), 1155-1164.
Review
For citations:
Moroz E.V., Sokolov A.A., Artemkin E.N. Use of non-steroid anti-inflammatory preparations for prevention of acute pancreatitis after endoscopic retrograde cholangiopancreatography (literature review). Acta Biomedica Scientifica. 2015;(2):115-121. (In Russ.)
Views:
588
Email this article 
